



Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request **Ein Cyf / Our Ref: 23-E-035**

You asked:

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition:

- Aflibercept – 1976 (please note that this medication is also supplied as ward stock to the clinic/unit. Therefore we have indicated the number of units dispensed, rather than patients treated, as this information is not recorded on a clinic level by our centralised systems)
- Bevacizumab - 0
- Brolucizumab - 0
- Dexamethasone - 444
- Faricimab – 397 (please note that this medication is also supplied as ward stock to the clinic/unit. Therefore we have indicated the number of units dispensed, rather than patients treated, as this information is not recorded on a clinic level by our centralised systems)
- Ranibizumab - <5*

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Please note that the numbers provided below reflect Wet AMD patients only.

- Aflibercept - <5*
- Bevacizumab - 0
- Brolucizumab - 0
- Dexamethasone - 0
- Faricimab - 118
- Ranibizumab - 0



* Where fewer than 5 has been indicated we are unable to provide you with the exact number of patients as due to the low numbers, there is a potential risk of identifying individuals if this was disclosed. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

